E. Berga-Švītiņa, V. Pirsko, M. Nakazawa-Miklaševiča, J. Maksimenko, J. Gardovskis, E. Miklaševičs
{"title":"乳腺癌和/或卵巢癌患者中CHEK2和BRCA1双杂合子的外显率","authors":"E. Berga-Švītiņa, V. Pirsko, M. Nakazawa-Miklaševiča, J. Maksimenko, J. Gardovskis, E. Miklaševičs","doi":"10.2478/prolas-2023-0020","DOIUrl":null,"url":null,"abstract":"Abstract Germline pathogenic BRCA1 variants confer increased risk of breast and/or ovarian cancer. The penetrance of BRCA1 pathogenic variants is variable due to the effects of other genetic factors. The interaction between CHEK2 and BRCA1 proteins is crucial in homology directed DNA repair pathway. The aim of this study was to assess the effect of three pathogenic/likely pathogenic variants of the CHEK2 gene on BRCA1 pathogenic allelic variant penetrance. The analysis included 380 DNA samples of women with confirmed positive BRCA1 status for one of founder variants c.4035del and c.5266dup. The c.444+1G>A and c.470T>C variants of CHEK2 gene were identified by Sanger’s sequencing, and the del5395 variant was detected by multiplex PCR. The studied CHEK2 variants were found in 13 double heterozygous cases (c.444+1G>A, n = 1; c.470T>C, n = 11, del5395, n = 1). Although the prevalence of CHEK2 variants in the ovarian cancer group was comparatively high (5.41%), the increase of the ovarian cancer risk was not statistically significant (OR = 1.56; 95% CI: 0.32–9.94; p = 0.73). The association of the age at the onset of cancer with the presence of particular CHEK2 variant was not consistent.","PeriodicalId":20651,"journal":{"name":"Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.","volume":"14 1","pages":"137 - 140"},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Penetrance of CHEK2 and BRCA1 Double Heterozygotes in Breast and/or Ovarian Cancer Patients\",\"authors\":\"E. Berga-Švītiņa, V. Pirsko, M. Nakazawa-Miklaševiča, J. Maksimenko, J. Gardovskis, E. Miklaševičs\",\"doi\":\"10.2478/prolas-2023-0020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Germline pathogenic BRCA1 variants confer increased risk of breast and/or ovarian cancer. The penetrance of BRCA1 pathogenic variants is variable due to the effects of other genetic factors. The interaction between CHEK2 and BRCA1 proteins is crucial in homology directed DNA repair pathway. The aim of this study was to assess the effect of three pathogenic/likely pathogenic variants of the CHEK2 gene on BRCA1 pathogenic allelic variant penetrance. The analysis included 380 DNA samples of women with confirmed positive BRCA1 status for one of founder variants c.4035del and c.5266dup. The c.444+1G>A and c.470T>C variants of CHEK2 gene were identified by Sanger’s sequencing, and the del5395 variant was detected by multiplex PCR. The studied CHEK2 variants were found in 13 double heterozygous cases (c.444+1G>A, n = 1; c.470T>C, n = 11, del5395, n = 1). Although the prevalence of CHEK2 variants in the ovarian cancer group was comparatively high (5.41%), the increase of the ovarian cancer risk was not statistically significant (OR = 1.56; 95% CI: 0.32–9.94; p = 0.73). The association of the age at the onset of cancer with the presence of particular CHEK2 variant was not consistent.\",\"PeriodicalId\":20651,\"journal\":{\"name\":\"Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.\",\"volume\":\"14 1\",\"pages\":\"137 - 140\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2478/prolas-2023-0020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Multidisciplinary\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/prolas-2023-0020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Multidisciplinary","Score":null,"Total":0}
引用次数: 0
摘要
种系致病性BRCA1变异会增加乳腺癌和/或卵巢癌的风险。由于其他遗传因素的影响,BRCA1致病变异的外显率是可变的。CHEK2和BRCA1蛋白之间的相互作用在同源定向DNA修复途径中至关重要。本研究的目的是评估CHEK2基因的三种致病/可能致病变异对BRCA1致病等位基因变异外显率的影响。该分析包括380名女性的DNA样本,这些女性的BRCA1基因被证实为c.4035del和c.5266dup的创始变异之一。Sanger测序法鉴定CHEK2基因的C .444+1G>A和C . 470t >C变异,多重PCR检测CHEK2基因的del5395变异。所研究的CHEK2变异在13例双杂合病例中发现(c.444+1G>A, n = 1;C . 470t >C, n = 11, del5395, n = 1)。虽然CHEK2变异在卵巢癌组中患病率较高(5.41%),但卵巢癌风险增加无统计学意义(OR = 1.56;95% ci: 0.32-9.94;P = 0.73)。癌症发病年龄与特定CHEK2变异存在的关系并不一致。
Penetrance of CHEK2 and BRCA1 Double Heterozygotes in Breast and/or Ovarian Cancer Patients
Abstract Germline pathogenic BRCA1 variants confer increased risk of breast and/or ovarian cancer. The penetrance of BRCA1 pathogenic variants is variable due to the effects of other genetic factors. The interaction between CHEK2 and BRCA1 proteins is crucial in homology directed DNA repair pathway. The aim of this study was to assess the effect of three pathogenic/likely pathogenic variants of the CHEK2 gene on BRCA1 pathogenic allelic variant penetrance. The analysis included 380 DNA samples of women with confirmed positive BRCA1 status for one of founder variants c.4035del and c.5266dup. The c.444+1G>A and c.470T>C variants of CHEK2 gene were identified by Sanger’s sequencing, and the del5395 variant was detected by multiplex PCR. The studied CHEK2 variants were found in 13 double heterozygous cases (c.444+1G>A, n = 1; c.470T>C, n = 11, del5395, n = 1). Although the prevalence of CHEK2 variants in the ovarian cancer group was comparatively high (5.41%), the increase of the ovarian cancer risk was not statistically significant (OR = 1.56; 95% CI: 0.32–9.94; p = 0.73). The association of the age at the onset of cancer with the presence of particular CHEK2 variant was not consistent.